Soligenix Inc. Net Assets
Soligenix Inc. net assets. Based on the latest financial reports, Soligenix Inc. (SNGX) has net assets worth $6.65 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.50 Million) and total liabilities ($3.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Soligenix Inc. net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.65 Million |
| % of Total Assets | 63.29% |
| Annual Growth Rate | 4.59% |
| 5-Year Change | -50.65% |
| 10-Year Change | -28.46% |
| Growth Volatility | 326.62 |
Net Assets of Soligenix Inc. (1995–2025)
Net assets of Soligenix Inc. from 1995 to 2025. This chart illustrates how Soligenix Inc.'s net assets have evolved over time, based on quarterly financial data. See Soligenix Inc. (SNGX) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Soligenix Inc. (1995–2025)
The table below shows the annual net assets of Soligenix Inc. from 1995 to 2025. For live market cap and overall valuation, see market value of Soligenix Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.29 Million | +28.51% |
| 2024-12-31 | $4.12 Million | +63.26% |
| 2023-12-31 | $2.52 Million | +202.09% |
| 2022-12-31 | $-2.47 Million | -123.04% |
| 2021-12-31 | $10.72 Million | +186.56% |
| 2020-12-31 | $3.74 Million | +156.79% |
| 2019-12-31 | $1.46 Million | -76.80% |
| 2018-12-31 | $6.28 Million | -0.63% |
| 2017-12-31 | $6.32 Million | -14.57% |
| 2016-12-31 | $7.40 Million | +40502.25% |
| 2015-12-31 | $-18.31K | +88.10% |
| 2014-12-31 | $-153.89K | +91.30% |
| 2013-12-31 | $-1.77 Million | -149.84% |
| 2012-12-31 | $3.55 Million | -47.71% |
| 2011-12-31 | $6.79 Million | -7.70% |
| 2010-12-31 | $7.36 Million | -9.99% |
| 2009-12-31 | $8.17 Million | +313.44% |
| 2008-12-31 | $1.98 Million | -23.67% |
| 2007-12-31 | $2.59 Million | +333.69% |
| 2006-12-31 | $-1.11 Million | -172.54% |
| 2005-12-31 | $1.53 Million | -48.78% |
| 2004-12-31 | $2.98 Million | -43.11% |
| 2003-12-31 | $5.24 Million | +22.38% |
| 2002-12-31 | $4.29 Million | +263.02% |
| 2001-12-31 | $-2.63 Million | -124.93% |
| 2000-12-31 | $10.55 Million | +45.34% |
| 1999-12-31 | $7.26 Million | -50.64% |
| 1998-12-31 | $14.70 Million | -20.11% |
| 1997-12-31 | $18.40 Million | +1542.86% |
| 1996-12-31 | $1.12 Million | -18.73% |
| 1995-12-31 | $1.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Soligenix Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23679432900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Soligenix Inc. Net Assets Breakdown (December 2025)
Soligenix Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.09K | 0.19% |
| Other Comprehensive Income | $45.79K | 0.87% |
| Other Components | $250.29 Million | 4729.43% |
| Total Equity | $5.29 Million | 100.00% |
Soligenix Inc. Competitors by Market Cap
The table below lists competitors of Soligenix Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KWESST MICRO SYS.INC.
F:62UA
|
$7.75 Million |
|
Jenn Feng New Energy Co Ltd
TW:1538
|
$7.75 Million |
|
Turbon AG
F:TUR
|
$7.76 Million |
|
Airway
WAR:AWM
|
$7.76 Million |
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
$7.75 Million |
|
Indiana Resources Ltd
AU:IDA
|
$7.75 Million |
|
Bergenbio ASA
OL:BGBIO
|
$7.75 Million |
|
Caely Holdings Bhd
KLSE:7154
|
$7.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Soligenix Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,118,071 to 5,292,125, a change of 1,174,054 (28.5%).
- Net loss of 11,080,380 reduced equity.
- New share issuances of 12,164,943 increased equity.
- Other factors increased equity by 89,491.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.08 Million | -209.37% |
| Share Issuances | $12.16 Million | +229.87% |
| Other Changes | $89.49K | +1.69% |
| Total Change | $- | 28.51% |
Book Value vs Market Value Analysis
This analysis compares Soligenix Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.35x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $815.98 | $0.36 | x |
| 1996-12-31 | $44.21 | $0.36 | x |
| 1997-12-31 | $17574.02 | $0.36 | x |
| 1998-12-31 | $1898.16 | $0.36 | x |
| 1999-12-31 | $2024.03 | $0.36 | x |
| 2000-12-31 | $2595.02 | $0.36 | x |
| 2001-12-31 | $-586.43 | $0.36 | x |
| 2002-12-31 | $571.49 | $0.36 | x |
| 2003-12-31 | $539.20 | $0.36 | x |
| 2004-12-31 | $220.32 | $0.36 | x |
| 2005-12-31 | $92.19 | $0.36 | x |
| 2006-12-31 | $-52.16 | $0.36 | x |
| 2007-12-31 | $85.69 | $0.36 | x |
| 2008-12-31 | $58.22 | $0.36 | x |
| 2009-12-31 | $2342.86 | $0.36 | x |
| 2010-12-31 | $109.06 | $0.36 | x |
| 2011-12-31 | $92.96 | $0.36 | x |
| 2012-12-31 | $47.83 | $0.36 | x |
| 2013-12-31 | $-274.69 | $0.36 | x |
| 2014-12-31 | $-16.39 | $0.36 | x |
| 2015-12-31 | $-1.69 | $0.36 | x |
| 2016-12-31 | $495.40 | $0.36 | x |
| 2017-12-31 | $246.85 | $0.36 | x |
| 2018-12-31 | $114.37 | $0.36 | x |
| 2019-12-31 | $18.05 | $0.36 | x |
| 2020-12-31 | $32.67 | $0.36 | x |
| 2021-12-31 | $57.71 | $0.36 | x |
| 2022-12-31 | $-13.77 | $0.36 | x |
| 2023-12-31 | $5.20 | $0.36 | x |
| 2024-12-31 | $2.48 | $0.36 | x |
| 2025-12-31 | $1.02 | $0.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Soligenix Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -209.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.75x
- Recent ROE (-209.37%) is below the historical average (-142.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -86.20% | 0.00% | 0.00x | 1.04x | $-1.33 Million |
| 1996 | -175.00% | 0.00% | 0.00x | 1.12x | $-2.07 Million |
| 1997 | -17.39% | -3200.00% | 0.01x | 1.04x | $-5.04 Million |
| 1998 | -346.03% | -10900.00% | 0.01x | 2.57x | $-22.43 Million |
| 1999 | -103.37% | -750100000.00% | 0.00x | 1.28x | $-8.23 Million |
| 2000 | -45.48% | -479600000.00% | 0.00x | 1.30x | $-5.85 Million |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.37 Million |
| 2002 | -115.88% | 0.00% | 0.00x | 1.36x | $-5.39 Million |
| 2003 | -100.83% | -6309.62% | 0.01x | 1.19x | $-5.81 Million |
| 2004 | -196.81% | -588.68% | 0.20x | 1.70x | $-6.17 Million |
| 2005 | -308.89% | -153.45% | 0.91x | 2.21x | $-4.87 Million |
| 2006 | 0.00% | -352.92% | 1.64x | 0.00x | $-8.05 Million |
| 2007 | -238.00% | -490.06% | 0.33x | 1.46x | $-6.42 Million |
| 2008 | -173.08% | -148.14% | 0.69x | 1.70x | $-3.62 Million |
| 2009 | -73.82% | -214.28% | 0.30x | 1.15x | $-6.85 Million |
| 2010 | -100.40% | -379.21% | 0.21x | 1.26x | $-8.12 Million |
| 2011 | -35.03% | -31.05% | 0.93x | 1.21x | $-3.06 Million |
| 2012 | -117.23% | -132.37% | 0.67x | 1.32x | $-4.52 Million |
| 2013 | 0.00% | -312.00% | 0.39x | 0.00x | $-9.88 Million |
| 2014 | 0.00% | -95.23% | 1.01x | 0.00x | $-6.69 Million |
| 2015 | 0.00% | -89.31% | 1.19x | 0.00x | $-7.83 Million |
| 2016 | -43.87% | -31.06% | 1.02x | 1.39x | $-3.98 Million |
| 2017 | -113.09% | -131.57% | 0.57x | 1.51x | $-7.78 Million |
| 2018 | -141.72% | -169.81% | 0.50x | 1.67x | $-9.53 Million |
| 2019 | -642.05% | -290.94% | 0.41x | 5.34x | $-9.50 Million |
| 2020 | -472.72% | -916.25% | 0.10x | 5.32x | $-18.06 Million |
| 2021 | -117.05% | -37632.97% | 0.00x | 2.51x | $-13.62 Million |
| 2022 | 0.00% | -5519.34% | 0.02x | 0.00x | $-13.55 Million |
| 2023 | -243.45% | -731.60% | 0.09x | 3.88x | $-6.39 Million |
| 2024 | -200.74% | -6925.11% | 0.01x | 2.18x | $-8.68 Million |
| 2025 | -209.37% | 0.00% | 0.00x | 1.75x | $-11.61 Million |
Industry Comparison
This section compares Soligenix Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Soligenix Inc. (SNGX) | $6.65 Million | -86.20% | 0.58x | $7.75 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial fo… Read more